COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS

摘要

A method is provided of treating depression in mammals, including a human, a s well as depression and a concomitant disease, disorder or condition exemplified by, but not limited to, anxiety, sleep disorder and post-traumat ic stress disorder. The method comprises administering to the mammal in effecti ve amount a combination of active ingredients comprising a) an alpha-2delta (A2 D) ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said 2 D ligand or said prodrug and, active agents selected from; (b) a selective serotonin re-uptake inhibitor (SSRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) a selecti ve noradrenaline re-uptake inhibitor (SNRI) or a prodrug thereof or a pharmaceutically acceptable salt of said NRI or said prodrug and mixtures of (b) and (c). A pharmaceutical composition comprising a therapeutically effective amount (a) an A2D ligand or a pro g thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and active agents selecte d from; (b) an SSRI or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) an SNR or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said is prodrug and mixture s of (b) and (c) is also provided. Preferredactive ingredients for the treatment and the pharmaceutical composition include pregabalin, gabapentin, sertraline and reboxetine.